Result of AGM

RNS Number : 9345T

Physiomics PLC

19 November 2019

 

19 November 2019          

Physiomics plc

("Physiomics" or "the Company")

Result of AGM

The Company held its Annual General Meeting at its offices in Oxford on 19 November 2019 and is pleased to announce that all resolutions put to shareholders were duly passed.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

 

END

 

 

RAGDMMMMZLLGLZM